Sygnature Discovery and RenaSci have inked a deal to provide an integrated service to accelerate client projects in metabolic and CNS disorders from discovery into development.

Sygnature undertakes integrated drug discovery projects for pharmaceutical and biotechnology companies worldwide, from target validation to development candidate. RenaSci provides an integrated blend of consultancy and experimental services to the global pharmaceutical industry to help maximize research productivity and streamline drug development.

“We are pleased to have entered into a strategic alliance with Sygnature Discovery.  Sygnature has established a reputation for providing integrated drug discovery resource and expertise with the ability to accelerate their clients’ drug discovery projects,” said Rob Jones, executive director, RenaSci. “We have been collaborating with Sygnature for a number of years on projects which have delivered drug candidates, so we already have a well-established working relationship.”

The strategic alliance combines the complementary skills and experience of RenaSci and Sygnature in metabolic diseases and CNS disorders. RenaSci will continue to provide pre-clinical services and consultancy independently, but will also be able to actively contribute to Sygnature’s fully-integrated drug discovery capability.

“RenaSci has gained a well-deserved reputation for excellence as an organization which offers high quality pre-clinical research services focused on metabolic and CNS disorders,” said Simon Hirst, chief executive officer, Sygnature. “The senior management has extensive experience of drug development gained at BASF Pharma and Boots Pharmaceuticals. They have initiated and led numerous projects, which have successfully progressed compounds from the laboratory into clinical development, and then onto the market. Sygnature already has a long-term and close working relationship with RenaSci, which will be cemented through this alliance. It enables Sygnature Discovery to offer its customers a world class, metabolic disease and CNS-focused integrated drug discovery package where novel compounds can be designed, synthesised and tested in vitro at Sygnature and then assessed in vivo at RenaSci in disease-relevant models.”